Krystal Biotech, Inc.
Moat Score — Krystal Biotech, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Krystal's proprietary engineered HSV-1 vector platform underlies an already-approved, redosable gene therapy (VYJUVEK) and six-plus additional pipeline programs, representing a genuinely differentiable, multi-indication technology base rather than a single-asset patent. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a commercial-stage biotech with real but concentrated product revenue, Krystal has no demonstrated low-cost manufacturing or structural cost edge over larger, better-resourced rivals like CSL, Sanofi, or Vertex in its pipeline markets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | VYJUVEK's status as the only redosable gene therapy for a severe rare disease (DEB) with few alternatives gives Krystal real specialty-pharma pricing power, evidenced by $341.2 million in cumulative net product revenue since a 2023 launch. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in gene therapy commercialization - prescribing and patient uptake depend on clinical efficacy and physician familiarity, not on other users making the product more valuable. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Patients and physicians established on VYJUVEK's redosing regimen for DEB face some switching friction versus unproven rivals from Abeona or Castle Creek, but DEB treatment decisions ultimately follow efficacy data, not platform lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Krystal's pipeline expansion into cystic fibrosis, AATD, and oncology pits it against numerous large, well-capitalized incumbents in each market, meaning its platform scale does not translate into exclusionary market position outside its core DEB niche. |